AUM-001
- Generic Name
- AUM-001
MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- AUM Biosciences Pte Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT05462236
- Locations
- 🇦🇺
Ballarat Oncology and Haematology, Wendouree, Victoria, Australia
🇦🇺Pindara Private Hospital, Gold Coast Cancer Care, Benowa, Queensland, Australia
🇦🇺Cabrini Hospital, Malvern, Victoria, Australia
Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies
Phase 1
Withdrawn
- Conditions
- Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)Ph- Acute Lymphoblastic Leukemia (Ph-ALL)Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+)Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- EDDC (Experimental Drug Development Centre), A*STAR Research Entities
- Registration Number
- NCT03414450
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath